A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Matti Aapro; H. S. Rugo; Antônio Rossi; Giada Rizzi; Maria Elisa Borroni; Igor Bondarenko; Tomasz Sarosiek; Cristina Oprean; Servando Cardona‐Huerta; Vito Lorusso; M. Karthaus; Lee S. Schwartzberg; Steven M. Grunberg

doi:10.1093/annonc/mdu101

Keywords

PalonosetronAntiemeticMedicineChemotherapy-induced nausea and vomitingNauseaVomitingAprepitantOndansetronChemotherapyInternal medicineAnesthesiaGastroenterology

Affiliated Institutions

Related Publications

Ximelagatran vs Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation

Gregory W. Albers , Hans‐Christoph Diener , Lars Frison +8 more

The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in pat...

2005 JAMA 660 citations

Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia

Courtney D. DiNardo , Keith W. Pratz , Vinod Pullarkat +13 more

Abstract Older patients with acute myeloid leukemia (AML) respond poorly to standard induction therapy. B-cell lymphoma 2 (BCL-2) overexpression is implicated in survival of AML...

2018 Blood 1764 citations

Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D.

Amita Patnaik , Mark A. Socinski , Matthew A. Gubens +7 more

8011 Background: Pembro is a potent anti–PD-1 monoclonal antibody. IPI, an anti–CTLA-4 antibody, has shown activity in advanced NSCLC. In melanoma, combined anti–PD-1 and anti–C...

2015 Journal of Clinical Oncology 68 citations

Irinotecan Plus Oxaliplatin and Leucovorin-Modulated Fluorouracil in Advanced Pancreatic Cancer—A Groupe Tumeurs Digestives of the Fédération Nationale des Centres de Lutte Contre le Cancer Study

Thierry Conroy , B Paillot , Éric François +10 more

Purpose To evaluate response rate and toxicity of irinotecan and oxaliplatin plus fluorouracil (FU) and leucovorin (Folfirinox) in advanced pancreatic adenocarcinoma (APA). Pati...

2005 Journal of Clinical Oncology 238 citations

Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC).

Julie R. Brahmer , Leora Horn , Scott Antonia +9 more

8030 Background: The immune checkpoint receptor programmed death-1 (PD-1) negatively regulates T-cell activation. Nivolumab, a PD-1 receptor blocking antibody, was evaluated in ...

2013 Journal of Clinical Oncology 74 citations

Publication Info

Year: 2014
Type: article
Volume: 25
Issue: 7
Pages: 1328-1333
Citations: 241
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

241

OpenAlex

Cite This

APA Style

                            
                                
                                    Matti Aapro, 
                                
                                    H. S. Rugo, 
                                
                                    Antônio Rossi
                                
                                et al.
                            
                            (2014). 
                            A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. 
                            Annals of Oncology
                            , 25
                            (7)
                            , 1328-1333.
                            https://doi.org/10.1093/annonc/mdu101
                        

Identifiers

DOI: 10.1093/annonc/mdu101